129 related articles for article (PubMed ID: 32512484)
21. Corrigendum to "Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors" [Eur. J. Med. Chem. 167 (2019) 1-9].
Patel H; Jadhav H; Ansari I; Pawara R; Surana S
Eur J Med Chem; 2020 Aug; 200():112413. PubMed ID: 32512481
[No Abstract] [Full Text] [Related]
22. Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
Ge H; Zhang W; Yuan K; Xue H; Cheng H; Chen W; Xie Y; Zhang J; Xu X; Yang P
Eur J Med Chem; 2022 Jan; 228():114041. PubMed ID: 34902733
[No Abstract] [Full Text] [Related]
23. Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].
Li ZH; Zhao TQ; Liu XQ; Zhao B; Wang C; Geng PF; Cao YQ; Fu DJ; Jiang LP; Yu B; Liu HM
Eur J Med Chem; 2019 Nov; 181():111387. PubMed ID: 31376565
[No Abstract] [Full Text] [Related]
24. Corrigendum to "New desulfured troglitazone derivatives: Improved synthesis and biological evaluation" [Eur. J. Med. Chem. 187 (2020) 111939].
Dupommier D; Muller C; Comoy C; Mazerbourg S; Bordessa A; Piquard E; Pawlak M; Piquard F; Martin H; De Fays E; Grandemange S; Flament S; Boisbrun M
Eur J Med Chem; 2020 Dec; 208():112834. PubMed ID: 32966897
[No Abstract] [Full Text] [Related]
25. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
[No Abstract] [Full Text] [Related]
26. Corrigendum to "From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action" [Eur. J. Med. Chem. 204 (2020) 112481].
Tran QTN; Tan DWS; Wong WSF; Chai CLL
Eur J Med Chem; 2021 Jan; 209():112943. PubMed ID: 33097302
[No Abstract] [Full Text] [Related]
27. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91].
Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
Eur J Med Chem; 2020 Sep; 202():112633. PubMed ID: 32688164
[No Abstract] [Full Text] [Related]
28. Corrigendum to "Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5" [Eur. J. Med. Chem. 238 (2022) 114446].
Fang Z; Mu B; Liu Y; Guo N; Xiong L; Guo Y; Xia A; Zhang R; Zhang H; Yao R; Fan Y; Li L; Yang S; Xiang R
Eur J Med Chem; 2023 Jul; 255():115368. PubMed ID: 37119665
[No Abstract] [Full Text] [Related]
29. Corrigendum to 'Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-b1 pathway' [Eur. J. Med. Chem. 157 (2018) 229-247].
Li X; Lu C; Liu S; Liu S; Su C; Xiao T; Bi Z; Sheng P; Huang M; Liu X; Wei Y; Zhao L; Miao S; Mao J; Huang K; Gao S; Liu N; Qi M; Liu T; Qin S; Wei L; Sun T; Ning W; Yang G; Zhou H; Yang C
Eur J Med Chem; 2019 Feb; 163():403. PubMed ID: 30530191
[No Abstract] [Full Text] [Related]
30. Corrigendum to <' Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors' [Eur. J. Med. Chem. 211 (2021), 113109].
Alvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2021 Nov; 224():113703. PubMed ID: 34284231
[No Abstract] [Full Text] [Related]
31. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Sep; 201():112404. PubMed ID: 32526554
[No Abstract] [Full Text] [Related]
32. Corrigendum to "Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease" [Eur. J. Med. Chem. 163 (2019), 307-319. DOI: 10.1016/j.ejmech.2018.11.040].
Tang YW; Shi CJ; Yang HL; Cai P; Liu QH; Yang XL; Kong LY; Wang XB
Eur J Med Chem; 2024 Jun; ():116591. PubMed ID: 38890013
[No Abstract] [Full Text] [Related]
33. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
[No Abstract] [Full Text] [Related]
34. Corrigendum to 'Synthesis and biological evaluation of 7-methoxy-1-(3,4,5-trimethoxyphenyl)-4,5-dihydro-2H-benzo[e]indazoles as new colchicine site inhibitors' [Bioorgan. Med. Chem. Lett. 29 (2019) 2632-2634].
Jiang J; Zhang Q; Guo J; Fang S; Zhou R; Zhu J; Chen X; Zhou Y; Zheng C
Bioorg Med Chem Lett; 2021 Jun; 41():128015. PubMed ID: 33875347
[No Abstract] [Full Text] [Related]
35. Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725].
Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Aug; 199():112406. PubMed ID: 32408215
[No Abstract] [Full Text] [Related]
36. Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479].
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2023 Nov; 259():115692. PubMed ID: 37550158
[No Abstract] [Full Text] [Related]
37. Corrigendum to "Synthesis of the pH-sensitive nanoparticles based on the acylhydrazone bonds conjugated doxorubicin and studies on their in vivo anti-tumor effects" [Eur. J. Med. Chem. 260 (2023) 115715].
Shi Y; Pan X; Xu S; Zhu H; Zhao B; Sun Z; Dong R; Li N; Hou X; Yang X
Eur J Med Chem; 2023 Dec; 262():115887. PubMed ID: 37867086
[No Abstract] [Full Text] [Related]
38. Corrigendum to"An insight into the medicinal perspective of synthetic analogs of indole: A review" [Eur. J. Med. Chem. 180 (2019) 562-612 11516].
Thanikachalam PV; Maurya RK; Garg V; Monga V
Eur J Med Chem; 2019 Dec; 183():111680. PubMed ID: 31520927
[No Abstract] [Full Text] [Related]
39. Corrigendum to 'Dihydroorotate dehydrogenase: A drug target for the development of antimalarials' [Eur. J. Med. Chem. 125 (2017) 640-651].
Singh A; Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2017 Mar; 128():346-347. PubMed ID: 28241929
[No Abstract] [Full Text] [Related]
40. Corrigendum to "Photocytotoxic oxovanadium(IV) complexes of ferrocenyl-terpyridine and acetylacetonate derivatives" [Eur. J. Med. Chem. 92 (2015) 332-341].
Balaji B; Balakrishnan B; Perumalla S; Karande AA; Chakravarty AR
Eur J Med Chem; 2019 Aug; 175():1. PubMed ID: 31055148
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
